Form 4 - Statement of changes in beneficial ownership of securities:
SEC Accession No. 0001593968-24-000477
Filing Date
2024-03-18
Accepted
2024-03-18 20:10:36
Documents
1
Period of Report
2024-03-14

Document Format Files

Seq Description Document Type Size
1 PRIMARY DOCUMENT primary_01.html 4  
1 PRIMARY DOCUMENT primary_01.xml 4 6796
  Complete submission text file 0001593968-24-000477.txt   8259
Mailing Address C/O ALLOGENE THERAPEUTICS, INC. 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address
Chang David D (Reporting) CIK: 0001611024 (see all company filings)

Type: 4 | Act: 34 | File No.: 001-38693 | Film No.: 24760745

Mailing Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080
Business Address 210 EAST GRAND AVENUE SOUTH SAN FRANCISCO CA 94080 (650) 457-2700
Allogene Therapeutics, Inc. (Issuer) CIK: 0001737287 (see all company filings)

EIN.: 823562771 | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)